Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Burkitt's or Burkitt-like non-Hodgkin's lymphoma meeting 1 of the following risk criteria:~  * Low-risk disease meeting all of the following criteria:~    * Normal lactate dehydrogenase level~   * ECOG performance status 0-1~   * Ann Arbor stage I or II~   * No tumor mass over 10 cm in greatest diameter~ * High-risk disease, defined as disease not meeting low-risk criteria~* Newly diagnosed disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Hemoglobin ≥ 8.0 g/dL~* Absolute neutrophil count ≥ 500/mm³~* Platelet count ≥ 100,000/mm³ (50,000/mm³ if bone marrow involvement is documented)~* AST and ALT ≤ 3 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 3 times ULN~* Bilirubin ≤ 1.5 times ULN (3 times ULN if liver metastases are present)~* Creatinine clearance \> 50 mL/min~* Creatinine ≤ 2.0 mg/dL~* LVEF ≥ 45% by MUGA scan or echocardiogram~* No New York Heart Association class II-IV heart failure~* No clinically significant pericardial disease~* No myocardial infarction within the past 6 months~* No uncontrolled angina~* No severe uncontrolled ventricular arrhythmias~* No ECG evidence of acute ischemia or active conduction system abnormalities~  * Investigator must document any baseline ECG abnormality as not medically relevant~* No other malignancy within the past year except for basal cell carcinoma of the skin or in situ carcinoma of the cervix~* No other serious medical or psychiatric illness that would preclude study compliance~PRIOR CONCURRENT THERAPY:~* Prior treatment with 1 course of any combination of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and/or prednisone\* (CHOP)-like therapy allowed, provided the following doses are not exceeded:~  * Rituximab 750 mg/m²~ * Cyclophosphamide 1,000 mg/m²~ * Doxorubicin hydrochloride 50 mg/m²~ * Vincristine 2 mg/m²~* No other investigational drugs within the past 14 days~* No other concurrent systemic, cytotoxic, investigational, or chemotherapy agents NOTE: \*No maximum dose restriction on steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alternating doxil/Magrath regimen & rituximab/Magrath regimen (Type: EXPERIMENTAL): Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.

Based on this trial design, predict the completion outcome and termination type (if applicable).